Example collocations logo

Medicines in sentence

439 examples of Medicines in a sentence

Intellectual Property for the Twenty-First-Century EconomyNEW YORK – When the South African government attempted to amend its laws in 1997 to avail itself of affordable generic medicines for the treatment of HIV/AIDS, the full legal might of the global pharmaceutical industry bore down on the country, delaying implementation and exacting a human cost.
The South African cabinet is preparing to finalize an IP policy that promises to expand access to medicines substantially.
These countries are mainly taking aim at the most visible manifestation of IP injustice: the accessibility of essential medicines.
Many people cannot buy the most basic medicines and have no access to modern medical services.
Most of the kids need large numbers of medicines.
By making today’s medicines, vaccines, and other health tools universally available – and by stepping up research efforts to develop tomorrow’s health tools – we could close the health gap between wealthy and poor countries within a generation.
In addition to the use of chemical weapons, the United Nations estimates that 2.5 million civilians lack food, water, and medicines, because some towns and villages are too hard to reach, with an estimated 250,000 people completely cut off from outside help.
A second commitment included in the joint declaration – to help ensure that medicines are used only when they are needed – may seem obvious, but in fact represents a major problem driving AMR.
Together, we can safeguard the curative powers of our medicines.
The chemical industryhelps other sectors produce a vast range of environmentally friendly, everyday productsthat consumers are increasingly demanding, including shampoos, mobile phones,paper, tennis shoes, clothes, medicines, and cars.
Life-Saving Killer DrugsLONDON – The harmful effects of medicines capture headlines worldwide.
Moreover, drug safety is a leading factor in determining how medicines are regulated.
In the tragedy’s wake, drug-development processes were adjusted in order to bolster medicines’ safety profile.
Doctors and their patients are now eager to gain early access to biopharmaceutical medicines – a new variety of injectable drugs, including proteins, nucleic acids, and vaccines that are produced using biotechnology.
The price of medicines has become increasingly important as the cost of developing new medicines such as biopharmaceuticals has risen.
Given the substantial discrepancy, cash-strapped health-care payers must assess whether the new generation of medicines represents value for money.
As a result, drug developers are increasingly aware that surmounting the regulatory hurdle is no longer enough; they must also satisfy the payer, who in effect has become a second gatekeeper to patients’ access to new medicines.
Increasing knowledge of genetics is producing a new generation of medicines specifically tailored for individual patients, posing yet another new challenge to the industry, regulators, and payers.
The continuation of pressure, arm-twisting, intimidation, and measures aimed at cutting off Iranians’ access to a whole range of necessities – from technology to medicines and foodstuffs – can only poison the atmosphere and undermine the conditions needed to make progress.
The threat is straightforward: bacteria and other microbes are becoming resistant to available medicines faster than new medicines are being developed.
We urgently need more resources to monitor resistance, stronger incentives for R&D, and innovative financing mechanisms to ensure widespread access to accurate diagnoses and quality medicines.
Since then, Global Fund programs have helped roughly one million Africans to receive anti-retroviral medicines to treat AIDS, financed the distribution of around 30 million bed nets to combat malaria, and supported treatment of around two million people with TB.
Malaria can be brought under decisive control through bed nets, indoor spraying of insecticides, and making medicines freely available to poor people in malaria-prone villages.
New antiretroviral medicines had been developed and were being used in rich countries, but were too expensive for the poorest.
Millions of poor people were dying of AIDS, even though the new medicines could have kept them alive.
Deaths from malaria were soaring, partly because poor countries’ health systems were dramatically underfunded, and partly because the malaria parasite had developed resistance to the usual medicines.
Yet the potential to control malaria was actually improving, thanks to several newly emerging technologies: long-lasting insecticide-treated bed nets to prevent the mosquitos from biting, better diagnostics to identify infections, and a new generation of highly effective medicines.
There were also cases of extreme MDR-TB, soon called XDR-TB, which resisted even the back-up medicines.
Over the objection of the aid skeptics, the Global Fund provided financial support for massive free distribution of bed nets, diagnostics, and medicines to address malaria.
Back in 2000, before the Global Fund was established, infected people in developing countries died of AIDS without any chance to receive life-saving antiretroviral medicines.
Back